Skip to main content

Table 2 Weighted mean validation measures for categorical variables in Report of Verified Case of Tuberculosis (RVCT)

From: Assessing the validity of tuberculosis surveillance data in California

#* RVCT Variable Concordance (95% CI) % Sensitivity of Reported Value (95% CI) % Predictive Value of Reported Positive Value (95% CI) %
  DEMOGRAPHIC
1 Sex 98.1 (96.7, 99.0) 99.7 (98.0, 99.9) 97.5 (95.3, 98.6)
2 Race 97.7 (96.3, 98.6) ND ND ND ND
     White ND ND 99.2 (97.5, 99.7) 97.0 (94.4, 98.4)
     Black ND ND 95.3 (87.1, 98.4) 97.9 (88.8, 99.7)
     Asian-Pacific Islander ND ND 97.5 (94.9, 98.8) 98.4 (96.3, 99.3)
     American Indian/Alaska Native ND ND 50.0 (12.8, 87.2) 100.0 -§
3 Ethnicity 98.5 (97.2, 99.1) 97.6 (94.7, 98.9) 98.1 (95.5, 99.2)
  Country of origin       
4    U.S.-born 98.9 (97.7, 99.4) 99.1 (95.1, 99.9) 96.6 (92.8, 98.4)
5    Other country of origin 96.0 (93.6, 97.5) ND ND ND ND
6 Occupation 84.4 (80.7, 87.5) ND ND ND ND
     Health care worker ND ND 78.2 (46.4, 93.7) 70.5 (41.3, 89.0)
     Migratory agricultural worker ND ND 51.8 (25.1, 77.5) 81.1 (38.3, 96.7)
     Other occupation ND ND 76.4 (69.8, 81.9) 89.0 (83.3, 92.9)
     Not employed within past 24 months ND ND 93.5 (89.5, 96.0) 82.2 (76.9, 86.5)
7 Resident of long-term care facility at diagnosis 98.3 (97.1, 99.0) 67.8 (47.1, 83.3) 76.8 (57.8, 88.9)
8 Resident of correctional facility at diagnosis 99.0 (97.7, 99.6) 69.7 (45.7, 86.3) 100.0 -
  SOCIAL AND BEHAVIORAL RISK FACTORS
9 Homeless within past 1–2 years|| 99.1 (96.9, 99.7) 97.3 (92.6, 99.0) 95.1 (75.9, 99.2)
10 Injecting drug user within past year 98.1 (96.5, 99.0) 63.5 (41.5, 81.0) 86.5 (59.8, 96.5)
11 Non-injecting drug user within past year 96.6 (94.6, 97.9) 70.1 (55.2, 81.7) 90.9 (74.6, 97.1)
12 Excess alcohol use within past year 91.8 (88.8, 94.0) 69.9 (61.0, 77.6) 96.8 (89.3, 99.1)
  DIAGNOSTIC AND CLINICAL
13 Previous TB 94.6 (92.3, 96.2) 57.6 (45.0, 69.3) 93.5 (81.9, 97.9)
14 Site of disease 92.5 (90.4, 94.2) ND ND ND ND
     Pulmonary only ND ND 96.7 (94.6, 97.9) 96.2 (94.3, 97.4)
     Extra-pulmonary only ND ND 98.6 (96.8, 99.4) 81.6 (74.4, 87.0)
     Both pulmonary and extra-pulmonary ND ND 51.1 (39.7, 62.4) 86.9 (73.9, 94.0)
15 Sputum smear 89.6 (86.0, 92.3) 90.5 (85.8, 93.7) 92.2 (87.9, 95.1)
16 Sputum culture 96.8 (94.2, 98.2) 100.0 - 96.8 (94.2, 98.2)
17 Smear of tissue/body fluids (non-sputum) 49.2 (38.4, 60.0) 31.2 (21.0, 43.6) 98.7 (98.1, 99.2)
18    Tissue/body fluid type (non-sputum) 76.4 (59.3, 87.8) ND ND ND ND
19 Culture of tissue/body fluid (non-sputum) 98.2 (94.6, 99.4) 100.0 - 98.2 (94.6, 99.4)
20    Tissue/body fluid type (non-sputum) 73.9 (66.0, 80.6) ND ND ND ND
  Chest x-ray       
21    Abnormal/normal 96.0 (94.0, 97.3) 99.1 (97.6, 99.7) 96.8 (94.8, 98.0)
22    If abnormal: cavitary/non-cavitary** 90.9 (88.0, 93.2) 75.1 (66.3, 82.3) 86.2 (78.0, 91.7)
23    If abnormal: stable/worsening/improving 46.8 (37.0, 56.9) ND ND ND ND
  Stable ND ND 49.9 (36.0, 63.7) 53.7 (39.0, 67.9)
  Worsening ND ND 52.0 (38.0, 65.7) 51.7 (37.8, 65.4)
  Improving ND ND 26.9 (8.7, 58.6) 19.8 (6.5, 46.8)
24 Initial drug susceptibility testing done 100.0 - 100.0 - 100.0 -
  Results of initial drug susceptibility testing††       
25    Isoniazid 99.2 (98.1, 99.7) 92.5 (82.6, 97.0) 100.0 -
26    Rifampin 100.0 - 100.0 - 100.0 -
27    Pyrazinamide 92.1 (89.3, 94.2) 88.1 (68.8, 96.1) 100.0 -
28    Ethambutol 100.0 - 100.0 - 100.0 -
29    Streptomycin 98.3 (96.8, 99.1) 93.2 (78.8, 98.0) 92.0 (78.7, 97.3)
  TREATMENT AND CASE MANAGEMENT
  Initial treatment regimen       
30    Isoniazid 98.2 (96.8, 99.0) 99.6 (98.8, 99.9) 98.6 (97.2, 99.3)
31    Rifampin 98.7 (97.5, 99.4) 99.9 (99.7, 100.0) 98.8 (97.6, 99.4)
32    Pyrazinamide 96.7 (95.1, 97.8) 98.1 (96.7, 98.9) 98.4 (97.1, 99.1)
33    Ethambutol 95.9 (94.0, 97.2) 98.8 (97.4, 99.4) 96.5 (94.6, 97.8)
34    Streptomycin 98.7 (97.7, 99.3) 40.3 (16.3, 70.1) 38.1 (14.1, 69.9)
35 Sputum culture conversion documented 85.4 (81.1, 88.8) 93.3 (89.5, 95.7) 87.8 (83.0, 91.3)
36 Reason therapy stopped‡‡ 97.9 (96.4, 98.8) ND ND ND ND
     Completion of therapy ND ND 97.8 (96.0, 98.8) 100.0 -
     Lost/uncooperative or refused therapy ND ND 98.4 (98.4, 98.4) 62.9 (46.1, 77.1)
     Died ND ND 99.2 (96.6, 99.8) 93.3 (84.2, 97.4)
37 Provider type 73.4 (69.8, 76.7) ND ND ND ND
     Health Department only (HD) ND ND 74.7 (69.7, 79.1) 90.3 (86.7, 93.0)
     Private/Other only ND ND 79.6 (74.6, 83.9) 80.0 (74.2, 84.8)
     Both HD and Private/Other ND ND 38.6 (26.4, 52.5) 18.1 (12.0, 26.4)
38 Therapy administration 48.6 (44.4, 52.8) ND ND ND ND
     Directly Observed Therapy (DOT) only ND ND 29.7 (10.5, 60.4) 1.1 (0.4, 2.9)
     Self-administered Therapy (SAT) only ND ND 72.0 (66.7, 76.7) 88.3 (83.1, 92.0)
     Both DOT and SAT ND ND 26.4 (21.3, 32.2) 82.7 (73.1, 89.4)
39 Final drug susceptibility testing done ‡‡ 100.0 - 100.0 - 100.0 -
  Results of final drug susceptibility testing††§§       
40    Isoniazid 100.0 - 100.0 - 100.0 -
41    Rifampin 98.4 (97.3, 99.0) 92.6 (79.7, 97.5) 100.0 -
42    Pyrazinamide 90.5 (59.5, 98.4) - - - -
43    Ethambutol 90.3 (59.0, 98.4) - - - -
44    Streptomycin 100.0 - 100.0 - 100.0 -
  1. Note: All results are presented as survey-weighted mean estimates for the statewide cohort from which the sample was drawn.
  2. * Variable number (see Table 1)
  3. † Confidence interval
  4. ‡ Not determined, by design
  5. § No value computed (e.g., division by 0)
  6. || RVCT defines homeless within 1 year of diagnosis; medical record review defined homeless within 2 years of diagnosis
  7. ** RVCT values: cavitary, non-cavitary consistent with TB, non-cavitary not consistent with TB; medical record review values: cavitary, abnormal/non-cavitary
  8. †† As a result of a very small number of second-line drug susceptibility test results, these results are not presented.
  9. ‡‡ Excludes 9 cases: 1 case without TB; 5 cases reported as 'moved' on RVCT; 3 cases reported as 'other" on RVCT
  10. §§ Based on small number of cases with final susceptibility testing performed; therefore estimates are subject to considerable instability